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Background: Screening programmes exist in many countries for colorectal cancer. In recent years, there has been a
drive for a non-invasive screening marker of higher sensitivity and specificity. Stool-based pyruvate kinase isoenzyme
M2 (M2-PK) is one such biomarker under investigation. The aim of this systematic review and meta-analysis is to
determine the diagnostic accuracy, sensitivity and specificity of M2-PK as a screening tool in colorectal cancer.
Methods: A literature search of Ovid Medline, EMBASE and Google Scholar was carried out. The search strategy was
restricted to human subjects and studies published in English. Data on sensitivity and specificity were extracted and
pooled. Statistical analysis was conducted using summary receiver operating characteristic (SROC) curve methodology.
Results: A total of eight studies were suitable for data synthesis and analysis. Our analysis showed a pooled sensitivity
and specificity for M2-PK to be 79% (CI 73%–83%) and 80% (CI 73%–86%), respectively. The accuracy of M2-PK was 0.85
(0.82–0.88).
Conclusion: Faecal M2-PK assay has a relatively good sensitivity and specificity and high accuracy for screening
colorectal cancer.
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Introduction
Worldwide, colorectal cancer (CRC) is a common global
cancer accounting for approximately 694,000 deaths an-
nually (World Health Organisation). Early detection of
cancer is important for cancer survival; as a result,
screening programmes have been set up in a variety of
countries around the world. Whilst colonoscopy has
been used as a screening tool in some countries, it is in-
vasive, has inherent (although low) risks of perforation
[1] and the uptake by the population is low [2].
Another form of population screening is faecal occult
blood testing (FOBT) using either guaiac-based or
immunological-based (iFOBT) methods. Guaiac-based
faecal occult blood (FOBT) has been shown to have a* Correspondence: drmallikarjuna@gmail.com
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unless otherwise stated.sensitivity of 7.2%, whilst the newer iFOBT has a sensi-
tivity of 23.2% for colorectal cancer and significant pre-
cursor lesions [3]. According to a meta-analysis [4], the
sensitivity, specificity and positive predictive value of
immune chromatographic faecal occult blood test
(iFOBT) in CRC were 67%, 85% and 41%, respectively.
The low sensitivity of FOBT and iFOBT may result in
missing patients with colorectal cancers. Therefore, an
effective screening tool is necessary.
In recent years, efforts have been made to introduce a
more sensitive and specific marker in CRC screening.
One marker that has been investigated is pyruvate kinase
(M2-PK), an isoenzyme found in tumour cells. M2-PK is a
key enzyme within glycolysis, a process that catalyzes the
conversion of phosphoenolpyruvate (PEP) to pyruvate.
Depending upon the metabolic functions of the tissues,
different isoenzymes of pyruvate kinase are expressed.
During tumour formation, the tissue-specific isoenzymes. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
Table 1 Quality assessment of included studies using ‘QUADAS’ questionnaire
QUADAS questionnaire Abdullah et al.
2012 [13]
Parente et al.
2012 [14]
Mulder et al.
2007 [10]
Hardt et al.
2004 [15]
Koss et al.
2007 [16]
Tonus et al.
2006 [17]
Shastri et al.
2008 [11]
Haug et al.
2007 [18]
Was the spectrum of participants representative
of the patients who will receive the test in practice?
Yes Yes Yes Yes Yes Yes Yes Yes
Were selection criteria clearly described? Yes Yes Yes No Yes Yes Yes Yes
Was the reference standard likely to classify the
target condition correctly?
Yes Yes Yes Yes Yes Yes Yes Yes
Was the period between performance of the
reference standard and the index test short
enough to be reasonably sure that the target
condition did not change between the two tests?
Yes Yes Yes Yes Yes Yes Yes Yes
Did the whole sample or a random selection
of the sample receive verification using the
reference standard?
Yes Yes Yes Yes Yes Yes Yes Yes
Did participants receive the same reference
standard regardless of the index test result?
Yes Yes Yes Yes Yes Yes Yes Yes
Was the reference standard independent of
the index test? (That is, the index test did not
form part of the reference standard)
No Yes Yes Yes Yes No Yes Yes
Was the execution of the index test described
in sufficient detail to permit its replication?
Yes Yes Yes Yes Yes Yes Yes Yes
Was the execution of the reference standard
described in sufficient detail to permit its replication?
Yes Yes Yes Yes Yes Yes Yes Yes
Were the index test results interpreted without
knowledge of the results of the reference standard?
No Unclear Yes No No No No No
Was the reference standard results interpreted
without knowledge of the results of the index test?
No No No No No Unclear Yes Unclear
Were the same clinical data available when the
test results were interpreted as would be
available when the test is used in practice?
Yes Yes Yes Yes Yes Yes Yes Yes
Were un-interpretable, indeterminate or
intermediate test results reported?
No Yes Yes No No No Yes Unclear
Were withdrawals from the study explained? Unclear Yes Yes No No No Yes Unclear
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Figure 1 SROC curve of M2-PK isoenzymatic assay of faeces
samples for following eight studies: Haug et al. [18], Shastri
et al. [11], Tonus et al. [17], Koss et al. [16], Hardt et al. [15],
Mulder et al. [10], Parente et al. [14] and Abdullah et al. [13].
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expressed [5]. M2-PK is crucial for rapid tumour growth
and aerobic glycolysis during tumorigenesis [6,7].
Tumour M2-PK has been detected and quantified in
faeces (5). This has led to the development of faecal
M2-PK as a screening tool for colorectal cancer using
enzyme-linked immunoabsorbent assay (ELISA). How-
ever, there appears to be some contention in the litera-
ture regarding its utility. Some studies on faecal M2-PK
have shown a favorable sensitivity and specificity for
colorectal cancer and adenoma [8,9] whilst other stud-
ies have shown an unfavorable sensitivity and specificity
of faecal M2-PK [10-12].
The aim of this systematic review and meta-analysis is
to determine the overall sensitivity and specificity of
M2-PK in colorectal cancer and its potential as a popu-
lation screening tool.
Methods
Search strategy
A comprehensive literature search of PubMed, MED-
LINE (1946-Dec 2012), EMBASE (1974-Dec 2012) and
Google Scholar was carried out for articles in the English
language. The terms and keywords used included Pyru-
vate Kinase, M2-PK, colorectal cancer, colon cancer, rec-
tal cancer and pyruvate kinase M2.
Selection criteria and quality assessment
Articles with sensitivity and specificity results of faecal
M2-PK for colorectal cancer with confirmation of cancer
using colonoscopy and histology were included in our
study. Studies on plasma M2-PK, adenoma only, func-
tional bowel disorders only and inflammatory bowel dis-
eases only were excluded along with posters, systematic
reviews, meta-analysis, articles not in English and other
gastrointestinal cancers. Quality assessment of the in-
cluded studies was carried out using ‘QUADAS’ scoring
system (Table 1).
Data extraction and analysis
Data were extracted and reviewed by two reviewers (MU
and FA), and disagreements were resolved through dis-
cussion and consensus between the authors. Studies that
did not contain relevant data or where data were not
amenable to extraction were excluded. A pooled result
of sensitivity, specificity and diagnostic accuracy of M2-
PK from all included studies was done using Stata 13.1
statistical software. Results of the post-estimate are
depicted as forest plots, SROC curve and foreb plots. A
p value of <0.05 was deemed statistically significant.
Data synthesis
A total of eight studies were suitable for data synthesis.
Pooling of sensitivity and specificity results from theeight studies showed a combined sensitivity of M2-PK as
79% (CI 73%–83%) and the combined specificity to be
80% (CI 73%–86%) for M2-PK. The accuracy was 0.85
(0.82–0.88) (Figure 1).
Results
Search results returned a total of 132 articles, of which
125 were obtained through electronic searches and
seven were from manual reference matching (Figure 2).
After removal of duplicates, 130 abstracts were screened.
Of these, 35 articles were eligible for review of full text
with eight studies suitable for meta-analysis.
Demographics
A total of 2,654 patient data were pooled from the eight
articles. Of these, 407 patients had a confirmed diagnosis
of colorectal cancer on colonoscopy and histology. Using
M2-PK enzymatic assay, 317 (11.94%) of participants were
identified as true positives, 526 (19.82%) as false positives,
1,721 (64.85%) as true negatives and 90 (3.39%) as false
negatives.
Sensitivity
Pooling of data demonstrated the combined sensitivity
of M2-PK as a screening to be 79% (CI 73%–83%), Q =
12.85, df = 7.00, p = 0.08 (Figure 3) with I2 = 45.51 (1.19–
89.82). There was moderate heterogeneity in the in-
cluded studies. We also assessed the empirical Bayes of
Figure 2 A PRISMA diagram outlining the search strategy.
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with that of observed data (Figure 3) and found that the
observed sensitivity was overestimated in three studies
(study number 4, 6 and 7).
Specificity
Pooling of data also demonstrated a combined spec-
ificity of 80% (CI 73%–86%), Q = 48.80, df = 7.00,
p = <0.001 (Figure 3) with I2 = 85.65 (76.95–94.36).
There was considerable heterogeneity in the included
studies. We also assessed the empirical Bayes of thespecificity of the included studies and compared them
with that of observed data (Figure 4). The observed
specificity was overestimated in three studies (studies
3, 4 and 6). These three studies were found to be
outliers (Figure 5).
Accuracy
The diagnostic accuracy was calculated by measuring
the area under the curve (Figure 1) from the included
studies. The diagnostic accuracy of M2-PK for diagnos-
ing colorectal cancer was 0.85 (0.82–0.88).
Figure 3 Forest plots showing the sensitivity and specificity for individual studies with their 95% confidence intervals, combined
sensitivity and combined specificity from all the included studies.
Uppara et al. World Journal of Surgical Oncology  (2015) 13:48 Page 5 of 9Subgroup analysis
Removal of outliers from Figure 1 (studies numbered 3,
4, 6 and 7) has removed the effect of outliers outside the
95% prediction contour on the ROC curve in measuring
overall accuracy. All the studies were lying within the
95% prediction contour of measured accuracy (adjusted
accuracy), though it is lower than the observed accuracy
for eight studies.
The adjusted accuracy (Figure 6) was 0.80 (0.77–0.84).
The adjusted sensitivity was 0.73 (0.66–0.79) (Figure 7),
and the adjusted specificity was 0.76 (0.72–0.79) (Figure 7).
Heterogeneity whilst estimating sensitivity was nullified
after the removal of the outliers, but significant hetero-
geneity remained whilst estimating specificity (although
p value is 0.01).
Discussion
The result of this study suggests that M2-PK may have
a high sensitivity and specificity (significant hetero-
geneity was noted whilst estimating specificity) fordiagnosing colon cancer. Current screening methods
such as FOBT and iFOBT have a lower documented
sensitivity, specificity rates as well as a lower positive
predictive value [19]. Bleeding from the bowel due to
non-malignant causes can give rise to false positives in
FOBT and iFOBT. Conversely, small tumours may not
cause significant bleeding due to the absence of tumour
necrosis or angiogenesis and therefore result in a false-
negative test on FOBT. Tumour necrosis and angiogen-
esis are late events in the tumour progression, which
lowers the sensitivity of FOBTs for non-bleeding tu-
mours. In many countries such as the UK, positive
FOBT is a prerequisite to further invasive investiga-
tions such as colonoscopy. High false-positive rates,
therefore, result in potentially unnecessary colonos-
copies, which may be unpleasant for the patient and are
also costly.
Therefore, a screening modality that is non-invasive,
easy to use and possesses a high sensitivity and specifi-
city rate as well as a high predictive value is desirable.
Figure 4 Foreb plot.
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with colorectal cancer with a strong correlation between
the amount of faecal tumour M2-PK and tumour stage
[15]. Our results show M2-PK faecal assays to have a
sensitivity and specificity of 79% and 80%, respectively,
at a cutoff value of 4 units/μl, giving a higher sensitivity
than FOBT but a lower specificity in comparison. This
value is in keeping with studies such as Tonus et al.
[11,12,15,17]. With these sensitivity and specificity
values, M2-PK may therefore be an effective addition to
screening for bowel cancer along with FOBT and iFOBT
so that both sensitivity and specificity of the screening
tools can be kept at an optimum level as required.Furthermore, FOBT has been associated with a par-
ticularly low cancer pick-up rate in proximal cancers [3].
This appears to be a lesser problem with M2-PK as it
has a high sensitivity rate for proximal tumours [18,10].
In combination with iFOBT, PK-M2 may enhance the
overall pickup rate for proximal cancers [14].
However, there are cost implications associated with
M2-PK for use as a screening tool. A study by Koss and
colleagues in 2007 [16] showed the cost of M2-PK test
to be £13.50 per sample. This is substantially higher than
the cost of FOBT (£5.00 per person) [16]. But costs of
the colonoscopy or flexible sigmoidoscopy may outweigh
the costs of M2-PK if applied for false-positive patients
Figure 5 Graphical depictions of residual-based goodness-of-fit, bivariate normality, influence and outlier detection analyses.
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colonoscopy. Colonoscopy and flexible sigmoidoscopy is
more expensive than either FOBTs or M2-PK due to the
requirement of both technical expertise and instrumen-
tation costs. Also there is a risk of bowel damage/Figure 6 SROC curve of M2-PK isoenzymatic assay of faeces
samples for the following four studies (excluding the outliers):
Haug et al. [18], Shastri et al. [11], Hardt et al. [15] and
Abdullah et al. [13].perforation with invasive procedures such as colonos-
copy and flexible sigmoidoscopy.
Diagnostic accuracy is a good estimate of the true na-
ture of the test, though it does take into the account the
amount of heterogeneity whilst estimating combined
accuracy. M2-PK accuracy for diagnosing colorectal
cancer is 0.85. In this meta-analysis, we have analysed
colorectal cancer data from the included papers separ-
ately from the data for polyps and other benign condi-
tions such as inflammatory bowel disease. Amongst the
included papers, some papers have also reported that
faecal M2PK levels are slightly elevated in benign condi-
tions as well, although their levels are not as high as that
of colorectal cancer.
Conclusion
In conclusion, faecal M2-PK testing has a high sensitivity
and specificity rate as well as a high accuracy for diag-
nosing bowel cancer in a screened population. Although
more costly than FOBT, it has the potential to be used
as a screening tool in the general population.
Limitations of the study
1) Selection bias could have led to the recruitment of
more symptomatic patients in UK-based studies.
Henceforth, studies done in UK have reported very
high sensitivity and high specificity when compared
to other studies.
Figure 7 Forest plots showing the sensitivity and specificity for individual studies with their 95% confidence intervals, combined
sensitivity and combined specificity from four studies excluding the out liars.
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in these studies if one needs to compare strictly
against gold standard (colonoscopy) whilst assessing
the accuracy of the test.
3) Significant false positives were also reported in
some of the studies with the generic test ‘M2PK’ in
non-neoplastic conditions such as inflammatory
bowel diseases.
4) Cutoff values for ‘M2PK’ were not standardised to
differentiate between neoplastic and inflammatory
conditions of the bowel.
5) Estimation of ‘M2PK’ enzymatic activity by ELISA
technique (which was used in all the included
studies) has a disadvantage of reporting high false
positives as opposed to more accurate methods such
as PCR techniques.
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